about
Computerized techniques pave the way for drug-drug interaction prediction and interpretationThe impact of comorbidity on cancer and its treatmentPharmacogenomics of chemotherapeutic susceptibility and toxicitySystematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction networkMinimising treatment-associated risks in systemic cancer therapy.Data-driven prediction of adverse drug reactions induced by drug-drug interactions.DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome.Acceptance of oral chemotherapy in breast cancer patients - a survey study.Understanding CAM Natural Health Products: Implications of Use Among Cancer Patients and Survivors.Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening methodTherapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibitionCoprescription of Chinese Herbal Medicine and Western Medications among Prostate Cancer Patients: A Population-Based Study in TaiwanA survey on herbal management of hepatocellular carcinomaInvestigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trialsA pilot study on the impact of known drug-drug interactions in cancer patientsPharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicinModifiable risk factors for intracerebral hemorrhage: study of anticoagulated patientsCancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapyDrug interactions in childhood cancer.Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country.Optimizing chemotherapy: concomitant medication listsEvaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.Potential drug interactions in patients with a history of cancer.Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method.Clinically-relevant anticancer-antidepressant drug interactions.Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.Prevalence study on potential drug-drug interaction in cancer patients in Piacenza hospital's Onco-Haematology department.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.Phenytoin toxicity in a patient receiving 5-fluorouracil-based chemotherapy for metastatic colorectal cancer.Drug dispensings among elderly in the year before colon cancer diagnosis versus matched cancer-free controls.Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.Oral ethanol potentiates the loss of outer hair cells in cisplatin-exposed rats.Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center.
P2860
Q26741470-622C2875-0FA0-4B25-AE4B-DEFCC49D4B64Q26764935-60823211-1B77-4D85-A1E4-ED1BAB093877Q27025558-7DC6FE67-CBAF-4F71-A42B-ED23827E3EEEQ28488578-1B65C187-919F-46CE-AE24-8B2DB5B722DEQ33300964-D2888A72-1009-4EBB-BC73-B7B609B41E90Q33781632-4C75F413-8EE9-4DD5-8CF4-A1B2EDC54E18Q33860716-16B704A0-A40C-4B2C-81DD-AEBE584E93E8Q33870472-F180DB8B-00E9-4941-B1EB-29DA41F20A20Q33886054-E6703D80-5DAC-4FF9-94AA-142BA69DFD08Q34130767-D8042C98-A383-4382-AF18-92DCBBEF517EQ34453023-B3913DC9-041F-458B-B071-27DD5F031151Q35092019-BC5488AA-9C44-40C2-A9FA-80029F72B64FQ35116293-2EE6203D-4C0F-41C2-9B0C-8BAA364AA57EQ35172998-1AD28322-0211-451D-8559-24C759674118Q35813114-D7FA57F9-9E2E-4B57-BF4E-633B2C486985Q35827606-CE8B335A-5ABB-46FB-B88A-13AAFA3F51A5Q35878347-2DDC8DB6-F66E-4EFB-BD40-FFEDC69D880CQ35990349-596C2F1E-7B45-4C59-B58C-7F5F59E8A3B5Q36629243-168A8FD6-CDC5-47E2-B3B1-EBFB9EBAAEC5Q36835353-3B1E2D3B-F34E-4A59-948A-5C373518BC65Q36842939-D2010393-0D1A-4B4C-9EBF-EC081E873E09Q36898141-A0EA578E-14E5-4B1C-B9C1-6DD3D27679F3Q37268706-2EA84543-3902-41DE-BABA-AF95E148FE52Q37304704-C38A9B9A-EDA8-4084-BBDE-C62D256DF0B9Q37320052-B154F4BA-74FB-406F-A3D6-4B5E0052D689Q37692463-3CF1EDCE-DCCA-4160-AA55-11A1C2A898DEQ37719619-380852E4-E016-46AE-8B3B-977ACDBE5104Q37846001-2F107C54-85FF-4DA7-A957-FA500E8A433BQ37970709-750B30E3-E6E6-4A33-933C-88FCB5273BB3Q37995764-85214684-5303-4364-ADA5-69D8D5750406Q38118900-842AC8ED-972E-4826-A537-362605035ADDQ38356369-F9ED5377-4746-40E1-AD6D-2428A1FFA398Q38676169-D2799453-8EFC-4A15-8FC7-3ECE3593682FQ38981028-10C67669-4349-4215-82B0-4A197E23E372Q39182548-53A3A98F-72ED-4EAE-8135-518B0BD45C5EQ39371022-F0C60D9F-C9A1-4E70-83E3-D72E4D5BA3FDQ39465288-DA068372-D7DC-4431-B2D5-6B8B49859763Q41564295-D412BB63-1213-448C-B107-4B2A1FBDE547Q42516767-88D8007E-B3E4-4423-8735-59851473190CQ44557402-BD0C5F99-1D82-4AA2-8318-6850E664C641
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Drug interactions in oncology.
@ast
Drug interactions in oncology.
@en
type
label
Drug interactions in oncology.
@ast
Drug interactions in oncology.
@en
prefLabel
Drug interactions in oncology.
@ast
Drug interactions in oncology.
@en
P1433
P1476
Drug interactions in oncology.
@en
P2093
Jan H M Schellens
Jos H Beijnen
P304
P356
10.1016/S1470-2045(04)01528-1
P577
2004-08-01T00:00:00Z